Fosun International Granted Three Awards from Global Banking and Finance Review in the United Kingdom

Release time:2021-08-06 Content sourced from: Page View:

On 2 August 2021, Fosun International was noticed by Global Banking and Finance Review, a famous financial magazine in the United Kingdom, that Fosun International was granted three awards, namely “Corporate Social Responsibility (CSR) Awards - Best CSR Company Asia 2021”, “Brand of the Year Awards - Holding Group Brand of the Year China 2021” and “Business Awards - Most Innovative Holding Group China 2021”, respectively.




Fosun has been awarded by Global Banking and Finance Review in recognition of the Group’s positive contribution to the global pandemic. The awards also recognized Fosun’s collaboration with BioNTech from Germany in developing the mRNA-based COVID-19 vaccine. The vaccine is the most exciting innovative result of Fosun, which brings a gleam of hope towards the end of the global pandemic.


Relief the global pandemic, showing strong social responsibility


The raging COVID-19 pandemic has imposed tremendous challenges to the corporates worldwide since the beginning of 2020. However, many corporates have shown excellent resilience and responsiveness to minimize the impact of the pandemic on their businesses. Some of them even fully support anti-pandemic work and overcome the difficulties with society, which shows their strong social responsibility and sense of dedication.


Facing the impact of the pandemic, Fosun promptly activated the wartime mechanism and actively took up corporate social responsibilities while strengthening its organizational action. Since the outbreak of the COVID-19 pandemic on 24 January 2020, Fosun has initiated a global medical supplies deployment plan and demonstrated its “China Speed across the Globe” under its diversified business ecosystem. It has delivered millions of medical supplies to China’s frontline against the pandemic immediately from more than 20 countries across different time zones. As the overseas pandemic situation deteriorated, Fosun launched the second phase of actions combating the COVID-19 pandemic immediately by sending more supplies to major countries and regions affected by the pandemic.


At the end of April this year, the pandemic situation in India deteriorated rapidly. The Indian medical frontlines have a severe shortage of oxygen concentrators and have difficulty in coping with the surging patient demand. Fosun and its subsidiaries have made many rounds of donations at the earliest time possible. Fosun Trade has initiated the emergency deployment of around 20,000 oxygen concentrators, while Ahuja Hive, Fosun Hive’s Indian platform, donated 100,000 KN95 masks, ten oxygen concentrators, five medical ventilators, and 1,000 protective suits, etc. Fosun is continuing to deploy medical supplies and support globally without being relaxed. 


Recently, the pandemic situation in Nanjing tugged the heartstrings of every citizen in China. On 30 July 2021, Fosun's Fight Against COVID-19 Global Central Command was requested to support the combating of the pandemic in Nanjing by the Health Commission of Jiangning District, Nanjing Communist Youth League, Nanjing First Hospital, and Team Qinhuai of the Nanjing Fire Rescue Team. Until 31 July 2021 noon, the Central Command had provided 470,996 aid materials, including Fosun’s 3M N95 masks, medical nitrile gloves, disinfection supplies, and heatstroke prevention supplies, etc. The pandemic prevention materials were donated to the frontline through the collaboration of the Fosun Foundation, Nanjing Forte, Nanjing Iron & Steel, and Fosun Trade.


COVID-19 mRNA vaccine fighting against the pandemic, bringing a gleam of hope towards the end of the global pandemic


The awards granted by Global Banking and Finance Review were mainly in recognition of Fosun's positive contribution to the battle against the pandemic. Apart from leveraging its global resources and deploying protective supplies to countries and regions that seriously impacted by the pandemic, Fosun also steps forward to utilize its resources in the healthcare industry. Fosun and BioNTech from Germany jointly developed the COVID-19 mRNA vaccine, hoping to provide a concrete and effective solution to the pandemic.


Fosun utilizes its experience in the healthcare industry and strong innovation capability to develop COVID-19 mRNA vaccine jointly with BioNTech from Germany. On 15 March 2020, Fosun Pharma announced that its subsidiary, Fosun Pharmaceutical Industrial, has been licensed by BioNTech to exclusively develop and commercialize COVID-19 vaccines based on its proprietary mRNA technology platform in China. According to the agreement, Fosun Pharmaceutical Industrial is responsible for the clinical trials, application for a permit to introduce the vaccines into the market, the sales and marketing of the vaccine in Mainland China, Hong Kong SAR, Macao SAR, and Taiwan region.


In 2021, Fosun Pharma and BioNTech from Germany have been facilitating the development and launch of the COVID-19 mRNA vaccine actively in Greater China region. On 27 February 2021, the first batch of the COVID-19 mRNA vaccine COMIRNATY® (also known as BNT162b2, the Chinese name of the product: 復必  泰TM) arrived in Hong Kong SAR and Macao SAR and started vaccination at the beginning of March 2021.


Given the ever-escalating situation of the pandemic in Taiwan region in July 2021, Fosun Pharma’s subsidiary Fosun Industrial has reached advance procurement agreements for the mRNA-based COVID-19 vaccine BNT162b2 with Taiwan Semiconductor Manufacturing Co., Ltd. (“TSMC”), Hon Hai Precision Industry Co., Ltd. (“Hon Hai”), Yonglin Charity Foundation (“Yonglin”) and Zuellig Pharma, Inc. (“Zuellig Pharma”) respectively. Fosun Industrial will sell a total of 10 million doses of COVID-19 mRNA vaccines to Zuellig Pharma (pharmaceutical company with qualifications to import vaccines) entrusted by TSMC, Hon Hai and Yonglin. These COVID-19 mRNA vaccines will be donated to relevant agency of disease control of Taiwan region for local vaccination.


Besides, Fosun International was awarded “Holding Group Brand of the Year China 2021” and “Most Innovative Holding Group China 2021” by Global Banking and Finance Review, in recognition of Fosun’s corporate brand and innovation spirit. In recent years, Fosun has adhered to its positioning as an innovation-driven consumer group and actively solidifying its footholds in four major segments, namely Health, Happiness, Wealth, and Intelligent Manufacturing. Through technology and continuous innovation, Fosun is dedicated to providing high-quality products and services to global families.


Global Banking and Finance Review Magazine


Global Banking and Finance Review Magazine is a leading magazine in the United Kingdom. The Global Banking and Finance Review Awards were established in 2011 to accomplish companies with outstanding performances within the global finance industry. They recognize companies that bring innovations and achievements to the global financial world as well as companies that attach importance to corporate governance and social responsibility. The awards have evolved to include companies in banking, foreign exchange, insurance, hedge funds, pension funds, compliance and advisory, corporate governance, brokerage and exchange, project financing, binary options, investment management, technology, asset and wealth management, Islamic financing, exchange traded funds, real estate, corporate social responsibility, and other areas.

share
x

抖音二维码

扫一扫